Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06792994 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Study acronym: CLL2000
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2026 to Apr 2, 2026
    • Study sites: 1 to 2
    v4
  2. Start date: Aug 1, 2025 to Jan 1, 2026v3
  3. Start date: Jun 1, 2025 to Aug 1, 2025
    • Primary and study completion dates: Jun 1, 2030 to Aug 1, 2030
    • Collaborators: 5 to 4
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.
Trial Details
NCT Number NCT06792994
Lead Sponsor German CLL Study Group
Collaborators: GELLC (Grupo Español de Leucemia Linfocítica Crónica), Nordic Lymphoma Group, Polish Adult Leukemia Group, HOVON - Dutch Haemato-Oncology Association
Conditions
(from sponsor)		 Chronic Lymphocytic Leukemia
Related terms Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov